Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Secukinumab
Treatment for Psoriasis
Typical Dosage: 300mg SC at weeks 0, 1, 2, 3, 4, then every 4 weeks
Effectiveness
85%
Safety Score
58%
Clinical Trials
141
Participants
18K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
300mg SC at weeks 0, 1, 2, 3, 4, then every 4 weeks
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
70(Treat 70 patients to see 1 additional serious adverse event)
Confidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$95,000
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$96,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$150,000/QALY
QALYs Gained
1.3
Outcome-Based Costs
Cost per Responder
$124,805
Cost per Remission
$320,333
Secukinumab Outcomes
for Psoriasis
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+77%
Remission Rate
+30%
Common Side Effects
Nasopharyngitis
+12.3%
Diarrhea
+4.1%
Upper respiratory tract infection
+9.5%
Oral candidiasis
+1.7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Secukinumab in Psoriasis
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
NCT05320159COMPLETED
17.7K participants
OBSERVATIONAL
East Hanover, United States
Started: Feb 3, 2021
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
NCT04894890COMPLETED
1K participants
OBSERVATIONAL
Xicheng Direct, China +41 more
Started: Sep 26, 2021
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
NCT04711343COMPLETEDPHASE1
216 participants
INTERVENTIONAL
Changchun, China
Started: Jun 8, 2022
Immunologic Response to Secukinumab in Plaque Psoriasis
NCT02592018COMPLETEDPHASE4
15 participants
INTERVENTIONAL
San Francisco, United States
Started: Oct 1, 2016
Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
NCT03828643COMPLETED
156 participants
OBSERVATIONAL
Verona, Italy
Started: Mar 20, 2019
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
NCT05513014COMPLETED
1.52K participants
OBSERVATIONAL
East Hanover, United States
Started: Mar 21, 2021
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
NCT05368818COMPLETED
767 participants
OBSERVATIONAL
East Hanover, United States
Started: Dec 7, 2020
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
NCT02559622COMPLETEDPHASE3
151 participants
INTERVENTIONAL
Augsburg, Germany +22 more
Started: Apr 1, 2014
Safety and Efficacy of Secukinumab in Mild Psoriasis
NCT03131570COMPLETEDPHASE2
23 participants
INTERVENTIONAL
New York, United States
Started: May 23, 2017
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
NCT04571567COMPLETEDPHASE4
20 participants
INTERVENTIONAL
New York, United States
Started: Dec 2, 2019
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
NCT05650060COMPLETED
163 participants
OBSERVATIONAL
Bangkok, Thailand
Started: Jan 20, 2021
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
NCT05734482COMPLETEDPHASE1
130 participants
INTERVENTIONAL
Hefei, China
Started: Feb 15, 2023
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
NCT05215561COMPLETED
36 participants
OBSERVATIONAL
Nagoya, Japan +20 more
Started: Feb 14, 2022
Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients
NCT03149900COMPLETED
40 participants
OBSERVATIONAL
Lübeck, Germany
Started: Oct 1, 2016
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
NCT06126718COMPLETEDPHASE1
88 participants
INTERVENTIONAL
Qingdao, China
Started: Feb 21, 2024
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970COMPLETEDPHASE3
120 participants
INTERVENTIONAL
Le Mans, France +16 more
Started: May 20, 2015
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
NCT05344482COMPLETED
277 participants
OBSERVATIONAL
East Hanover, United States
Started: Jul 9, 2020
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
NCT06398652COMPLETEDPHASE3
336 participants
INTERVENTIONAL
Shanghai, China
Started: Aug 27, 2024
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
NCT01952015COMPLETEDPHASE3
12 participants
INTERVENTIONAL
Fukuoka, Japan +9 more
Started: Aug 21, 2013
Showing 20 of 146 total trials